Konecny GE - Search Results

1

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Konecny GE, et al. J Natl Cancer Inst. 2014 Sep 30;106(10):dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25269487 Free PMC article.

2

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

Pegram MD, Konecny G, Slamon DJ. Pegram MD, et al. Cancer Treat Res. 2000;103:57-75. doi: 10.1007/978-1-4757-3147-7_4. Cancer Treat Res. 2000. PMID: 10948442 Review. No abstract available.

3

Trastuzumab and chemotherapeutics: drug interactions and synergies.

Pegram MD, Lopez A, Konecny G, Slamon DJ. Pegram MD, et al. Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100. Semin Oncol. 2000. PMID: 11236023

4

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.

Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Konecny G, et al. Clin Cancer Res. 2001 Jun;7(6):1743-9. Clin Cancer Res. 2001. PMID: 11410515

5

Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.

Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Konecny G, et al. Clin Cancer Res. 2001 Aug;7(8):2448-57. Clin Cancer Res. 2001. PMID: 11489825

6

HER2 testing and correlation with efficacy of trastuzumab therapy.

Konecny G, Slamon DJ. Konecny G, et al. Oncology (Williston Park). 2002 Nov;16(11):1576, 1578. Oncology (Williston Park). 2002. PMID: 12469932 No abstract available.

7

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Konecny G, et al. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142. J Natl Cancer Inst. 2003. PMID: 12529347

8

Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?

Konecny GE, Wilson CA, Slamon DJ. Konecny GE, et al. J Natl Cancer Inst. 2003 Dec 17;95(24):1813-5. doi: 10.1093/jnci/djg134. J Natl Cancer Inst. 2003. PMID: 14679144 Review. No abstract available.

9

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Konecny GE, et al. Clin Cancer Res. 2004 Mar 1;10(5):1706-16. doi: 10.1158/1078-0432.ccr-0951-3. Clin Cancer Res. 2004. PMID: 15014023

10

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Pegram MD, et al. Among authors: konecny ge. J Natl Cancer Inst. 2004 May 19;96(10):739-49. doi: 10.1093/jnci/djh131. J Natl Cancer Inst. 2004. PMID: 15150302

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters